Takeda Pharmaceutical (TAK) Change in Taxes (2018 - 2026)

Takeda Pharmaceutical's Change in Taxes history runs 9 years deep, the most recent figure standing at -$411.1 million for Q1 2026.

• On a quarterly basis, Change in Taxes fell 24.85% year-over-year to -$411.1 million in Q1 2026; TTM through Mar 2026 was -$1.2 billion, a 6.59% decrease from a year earlier, with the FY2026 full-year figure at -$1.2 billion, down 7.02% from the prior year.
• Change in Taxes retreated to -$411.1 million in Q1 2026 per TAK's latest filing, from -$156.2 million in the prior quarter.
• Across five years, Change in Taxes topped out at -$156.2 million in Q4 2025 and bottomed at -$655.2 million in Q3 2022.
• The 5-year median for Change in Taxes is -$340.0 million (2023), against an average of -$331.9 million.
• Biggest YoY gain for Change in Taxes was 45.6% in 2023; the steepest drop was 111.5% in 2023.
• Year by year, Change in Taxes stood at -$410.1 million in 2022, then increased by 17.08% to -$340.0 million in 2023, then surged by 39.51% to -$205.7 million in 2024, then gained by 24.06% to -$156.2 million in 2025, then plunged by 163.23% to -$411.1 million in 2026.
• Per Business Quant, the three latest TAK Change in Taxes figures stand at -$411.1 million (Q1 2026), -$156.2 million (Q4 2025), and -$374.9 million (Q3 2025).